Paul Tudor Jones Revolution Medicines, Inc. Transaction History

Tudor Investment Corp Et Al

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$36.92 - $47.94 $1.41 Million - $1.84 Million	38,306 New	38,306 $1.74 Million
Q2 2023 Aug 14, 2023	BUY	$20.28 - $27.0 $1,399 - $1,863	69 Added 0.51%	13,583 $363,000
Q1 2023 May 15, 2023	BUY	$20.76 - $30.09 $84,597 - $122,616	4,075 Added 43.17%	13,514 $293,000
Q4 2022 Feb 14, 2023	BUY	$17.68 - $25.53 $166,881 - $240,977	9,439 New	9,439 $225,000
Q2 2022 Aug 15, 2022	SELL	$14.54 - $27.17 $650,272 - $1.22 Million	-44,723 Reduced 66.04%	22,998 $448,000
Q1 2022 May 16, 2022	BUY	$17.31 - $26.4 $1.17 Million - $1.79 Million	67,721 New	67,721 $1.73 Million
Q3 2021 Nov 15, 2021	SELL	$23.95 - $33.41 $1.82 Million - $2.53 Million	-75,797 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$29.0 - $47.44 $2.2 Million - $3.6 Million	75,797 New	75,797 $2.41 Million

299

179M

920K

1.06M

Ticker RVMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,697,600
Market Cap $3.35B
Description
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also d...

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.